Pre-made Teplizumab benchmark antibody ( Whole mAb, anti-CD3E therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-562
Pre-Made Teplizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Teplizumab (also known as PRV-031; formerly also known as MGA031 and hOKT3γ1(Ala-Ala)) is a humanized anti-CD3 monoclonal antibody that is being evaluated for treatment and prevention of type 1 diabetes mellitus (T1DM) by the biopharmaceutical company Provention Bio. Teplizumab has also been evaluated for treatment of renal allograft rejection, for induction therapy in islet transplant recipients, and for psoriatic arthritis.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Teplizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Preregistration|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Immune Tolerance Network;MacroGenics;National Institute of Diabetes and Digestive and Kidney Diseases;National Institutes of Health (USA);Provention Bio;Tolerance Therapeutics|
|Conditions Active||Type 1 diabetes mellitus|
|Conditions Discontinued||Multiple sclerosis;Psoriasis;Psoriatic arthritis|